Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,030,350
  • Shares Outstanding, K 61,457
  • Annual Sales, $ 77,430 K
  • Annual Income, $ -184,680 K
  • EBIT $ -266 M
  • EBITDA $ -250 M
  • 60-Month Beta 2.09
  • Price/Sales 53.44
  • Price/Cash Flow N/A
  • Price/Book 368.95

Options Overview Details

View History
  • Implied Volatility 43.88% ( -3.44%)
  • Historical Volatility 56.02%
  • IV Percentile 1%
  • IV Rank 1.47%
  • IV High 82.47% on 08/05/24
  • IV Low 43.30% on 10/11/24
  • Put/Call Vol Ratio 2.60
  • Today's Volume 18
  • Volume Avg (30-Day) 648
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 7,487
  • Open Int (30-Day) 10,447

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.74
  • Number of Estimates 10
  • High Estimate -0.54
  • Low Estimate -1.00
  • Prior Year -0.70
  • Growth Rate Est. (year over year) -5.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.61 +34.55%
on 10/31/24
68.58 -6.59%
on 11/11/24
+14.24 (+28.58%)
since 10/11/24
3-Month
43.57 +47.03%
on 08/22/24
68.58 -6.59%
on 11/11/24
+19.58 (+44.02%)
since 08/12/24
52-Week
27.12 +136.21%
on 11/13/23
68.58 -6.59%
on 11/11/24
+35.60 (+125.09%)
since 11/10/23

Most Recent Stories

More News
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

RYTM : 64.27 (-2.00%)
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

RYTM : 64.27 (-2.00%)
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

RYTM : 64.27 (-2.00%)
Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

RYTM : 64.27 (-2.00%)
Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

RYTM : 64.27 (-2.00%)
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

RYTM : 64.27 (-2.00%)
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END

PTN : 1.1800 (-1.67%)
RYTM : 64.27 (-2.00%)
VKTX : 60.81 (-3.43%)
GPCR : 37.50 (-3.10%)
NVO : 107.38 (-1.57%)
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

/PRNewswire/ -- The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in...

PTN : 1.1800 (-1.67%)
RYTM : 64.27 (-2.00%)
VKTX : 60.81 (-3.43%)
GPCR : 37.50 (-3.10%)
NVO : 107.38 (-1.57%)
What Will Amgen Buy Next?

The biotech could pursue these two budget-friendly targets.

REGN : 819.44 (-0.76%)
AMGN : 299.78 (-6.85%)
HZNP : 116.30 (+0.04%)
NTLA : 16.41 (-6.23%)
RYTM : 64.27 (-2.00%)
3 Breakout Growth Stocks to Buy for the Long Haul

These three have had big-time share gains backed up by breakthrough science.

BLTE : 81.00 (+3.00%)
TMDX : 91.58 (+2.77%)
RYTM : 64.27 (-2.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 71.13
2nd Resistance Point 69.85
1st Resistance Point 67.72
Last Price 64.27
1st Support Level 64.31
2nd Support Level 63.03
3rd Support Level 60.90

See More

52-Week High 68.58
Last Price 64.27
Fibonacci 61.8% 52.74
Fibonacci 50% 47.85
Fibonacci 38.2% 42.96
52-Week Low 27.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar